The Treatment Burden of Myopic Choroidal Neovascularization

Launched by POLICLINICO GASPARE RODOLICO - SAN MARCO CATANIA · Jun 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking into the treatment of myopic choroidal neovascularization (mCNV), a serious eye condition that can lead to vision loss in people with pathologic myopia, a condition where the eye becomes longer than normal. The study aims to understand how many injections of a specific medication (anti-VEGF) and hospital visits are needed to help stabilize the disease and lessen the burden on patients and their caregivers.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have certain eye measurements that indicate pathologic myopia, along with a diagnosis of mCNV in one eye. Those with other serious eye conditions or prior eye surgeries may not be included. If you join the study, you can expect to receive regular injections and attend follow-up visits to monitor your condition. This research is important as it aims to improve the management of mCNV and better understand how to support patients through their treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • axial length\>26 mm or refractive error (spherical equivalent) \<-6 Diopters
• • clinical changes typical of Pathologic myopia
• • diagnosis of subfoveal or juxtafoveal treatment-naïve myopic choroidal neovascularization (mCNV)
• • only one eye per patient was included in the analysis, in cases of patients treated bilaterally only the first eye treated was included
• Exclusion Criteria:
• • Extrafoveal mCNV location
• • Other retinal diseases
• • any inflammatory condition which may cause CNV including multifocal choroiditis, puntate inner choroidopathy and white dot syndrome
• • previous ocular surgery (except for cataract extraction performed before the baseline visit)
• • inferior quality imaging